RecruitingPhase 3NCT06934967
Study to Assess the Pharmacokinetics, Safety, and Tolerability of Iptacopan in Pediatric PNH Patients
Studying Paroxysmal nocturnal hemoglobinuria
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Novartis Pharmaceuticals
- Principal Investigator
- Novartis PharmaceuticalsNovartis Pharmaceuticals
- Intervention
- LNP023(drug)
- Enrollment
- 12 enrolled
- Eligibility
- 2-18 years · All sexes
- Timeline
- 2025 – 2031
Study locations (11)
- Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
- Childrens Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
- Novartis Investigative Site, Brasília, Federal District, Brazil
- Novartis Investigative Site, Natal, Rio Grande do Norte, Brazil
- Novartis Investigative Site, Porto Alegre, Rio Grande do Sul, Brazil
- Novartis Investigative Site, Santo André, São Paulo, Brazil
- Novartis Investigative Site, São Paulo, São Paulo, Brazil
- Novartis Investigative Site, Cali, Valle del Cauca Department, Colombia
- Novartis Investigative Site, Berlin, Germany
- Novartis Investigative Site, Genova, GE, Italy
- Novartis Investigative Site, Utrecht, Netherlands
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06934967 on ClinicalTrials.govOther trials for Paroxysmal nocturnal hemoglobinuria
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07154745A Study to Evaluate How Pozelimab + Cemdisiran Combination Therapy Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Whose Current Treatment is Not Working EfficientlyRegeneron Pharmaceuticals
- RECRUITINGNCT07457151Danicopan PMS in KoreaAstraZeneca
- RECRUITINGPHASE1NCT07462780A Phase I Clinical Trial to Evaluate CMS-D017 Following Single and Multiple Doses in Healthy ParticipantsShenzhen Kangzhe Biotechnology Co., Ltd.
- RECRUITINGPHASE1, PHASE2NCT07470762Study of Safety and Efficacy of HS-10542 in Patients With Paroxysmal Nocturnal HemoglobinuriaJiangsu Hansoh Pharmaceutical Co., Ltd.
- RECRUITINGPHASE1, PHASE2NCT07187401A First-in-Human Safety and Efficacy Study of ALN-CFB, a Small Interfering RNA (siRNA) Targeting Complement Factor B, in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria With Persistent Anemia on a C5 InhibitorRegeneron Pharmaceuticals
- ACTIVE NOT RECRUITINGNCT07413250Assess Long-Term Safety of Danicopan Add-on Therapy in Participants With Paroxysmal Nocturnal Hemoglobinuria: Analysis of IPIG-Registry DataAlexion Pharmaceuticals, Inc.
- RECRUITINGNCT07229235REAL-CARE: Real-world Effectiveness of Iptacopan in Italian Patients With Paroxysmal Nocturnal HemoglobinuriaNovartis Pharmaceuticals
- ACTIVE NOT RECRUITINGNCT07413679Long-term Safety of Danicopan: IPIG Registry-based Cohort StudyAlexion Pharmaceuticals, Inc.